A Phase IIa Study to Evaluate NBQ72S

A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.

Trial Details

NCT ID
NCT06810804
Phase
PHASE2
Sponsor
Nantong Bencao Quadriga Medical Technology Co. Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • NBQ72S
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • The patient must have histological evidence confirming the diagnosis of breast cancer with leptomeningeal metastasis: a. Breast cancer must be diag…
  • The patient's Karnofsky Performance Status (KPS) must be ≥60.
  • The patient must have adequate bone marrow function, including:
  • Absolute neutrophil count (ANC) ≥1,500/mm³ or ≥1.5 x 10⁹/L;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →